The partnership’s initial effort focuses on early detection of infectious diseases and other clinical conditions that affect patients in acute care hospitals.
Donald A. Johnson, Managing Director of MDI stated: “Life2’s artificial intelligence technology opens the door for exciting new software medical devices. MDI has deep experience in clinical trials, medical device technologies, pharmaceuticals, and healthcare in international markets. Our team looks forward to working with Life2 to bring new device innovation to the healthcare markets. We are actively conducting clinical trials for several new product ideas and hope to receive our first of many FDA 510k medical devices later this year.”
Life2’s Artificial Intelligence Engine provides hospitals empirical evidence of which clinical and procedural actions are most effective. It utilizes artificial intelligence, deep machine learning, cognitive augmentation and expert guidance to deliver real time patient based risk stratification, causality analysis and empirical intervention selection. An Evidence Engine powers an automated Machine Learning Feedback Loop that compiles the outcomes and measures the effectiveness of each action. This results in real time “course correction”, helping hospitals and clinicians optimize patient outcomes as well as quality and financial performance while reducing risk.
